- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- BMS-986504, Izalontamab Brengitecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 3,680
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
- Interventions
- PF-08052666
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
- Conditions
- Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Pancreatic Cancer, NSCLC, Mesothelioma, Ovarian Cancer, Ovarian Carcinoma, Head and Neck (HNSCC), Head and Neck Cancer, Renal Cell Carcinoma (Kidney Cancer), Triple Negative Breast Cancer (TNBC)
- Interventions
- No additional intervention administered in this long term follow-up study
- Other
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy
- Interventions
- Dexamthasone
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- NSCLC
- Interventions
- BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Glendale, California • Clermont, Florida • Orange City, Florida + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma
- Interventions
- PF-08046054, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Irvine, California • Orange, California + 12 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Radiofrequency ablation
- Device
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
- Interventions
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Other · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
- Conditions
- Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
- Interventions
- darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 64
- States / cities
- Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
- Conditions
- Advanced/Metastatic NSCLC
- Interventions
- Immunotherapy - PD-1 Blocker
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- NSCLC Stage IV, NSCLC, Recurrent
- Interventions
- Carboplatin, Pemetrexed, Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Nasser Hanna
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- thermal ablation with external beam radiation
- Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Advanced Solid Tumor, BRAF V600 Mutation
- Interventions
- ABM-1310, Cobimetinib
- Drug
- Lead sponsor
- ABM Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- San Francisco, California • Stanford, California • Miami, Florida + 4 more
- Conditions
- Lung Cancer
- Interventions
- PET/CT Scan
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
- Interventions
- immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology, biopsy
- Other · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Interventions
- XmAb®808, Keytruda® (pembrolizumab)
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
- Conditions
- Breast Cancer, Non-small Cell Lung Carcinoma
- Interventions
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
- Conditions
- Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Interventions
- aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
- Interventions
- PF-07799544, PF-07799933
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Biospecimen Collection, Bronchoscopy with Bronchoalveolar Lavage, Chemoradiotherapy, Computed Tomography, Diagnostic Laboratory Biomarker Analysis, Immune Checkpoint Inhibitor, Nasal Wash and Collection, Quality-of-Life Assessment, Questionnaire Administration, Spirometry
- Procedure · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Zanzalintinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- carboxyamidotriazole, placebo, quality-of-life assessment, laboratory biomarker analysis
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota